We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

83 hedge funds and large institutions have $661M invested in Crinetics Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 47 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

262% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 13

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

42% more capital invested

Capital invested by funds: $465M → $661M (+$196M)

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

4% more funds holding

Funds holding: 80 → 83 (+3)

5.91% less ownership

Funds ownership: 93.35% → 87.44% (-5.9%)

Holders
83
Holders Change
+3
Holders Change %
+3.75%
% of All Funds
1.44%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.09%
New
12
Increased
47
Reduced
13
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$12.4M
2
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$10.7M
3
BlackRock
BlackRock
New York
+$7.5M
4
SFM
Sphera Funds Management
Israel
+$6.15M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$5.96M

Top Sellers

Rank Fund Capital Flow
1
VVM
Versant Venture Management
California
-$21.3M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$9.96M
3
VC
Vivo Capital
California
-$8.11M
4
NHAS
Novo Holdings A/S
Denmark
-$4.15M
5
EAM
Eventide Asset Management
Massachusetts
-$3.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$3.43M -$330K -18,756 -9%
CCM
27
CAAS Capital Management
New York
$3.13M +$2.92M +166,317 New
N
28
Nuveen
North Carolina
$2.8M +$331K +18,842 +15%
Two Sigma Investments
29
Two Sigma Investments
New York
$2.19M +$1.03M +58,366 +101%
Deutsche Bank
30
Deutsche Bank
Germany
$1.68M +$72.4K +4,120 +5%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$1.6M +$891K +50,700 +148%
Victory Capital Management
32
Victory Capital Management
Texas
$1.5M -$62.2K -3,540 -4%
Norges Bank
33
Norges Bank
Norway
$1.37M +$689K +39,200 +117%
T. Rowe Price Associates
34
T. Rowe Price Associates
Maryland
$1.24M +$300K +17,060 +35%
Goldman Sachs
35
Goldman Sachs
New York
$1.15M -$1.08M -61,547 -50%
Citadel Advisors
36
Citadel Advisors
Florida
$1.14M +$1.07M +60,658 New
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$949K +$168K +9,556 +23%
Swiss National Bank
38
Swiss National Bank
Switzerland
$935K +$211K +12,000 +32%
AA
39
ALPS Advisors
Colorado
$933K -$177K -10,047 -17%
MWNA
40
Marshall Wace North America
New York
$824K +$767K +43,671 New
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$728K – – –
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$632K +$90.6K +5,154 +18%
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$594K +$118K +6,722 +27%
D.E. Shaw & Co
44
D.E. Shaw & Co
New York
$589K +$549K +31,232 New
AllianceBernstein
45
AllianceBernstein
Tennessee
$556K +$47.4K +2,700 +10%
Jacobs Levy Equity Management
46
Jacobs Levy Equity Management
New Jersey
$525K -$796K -45,317 -62%
BI
47
BVF Inc
California
$458K +$427K +24,280 New
Manulife (Manufacturers Life Insurance)
48
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$411K +$78.7K +4,481 +26%
SSA
49
Schonfeld Strategic Advisors
New York
$411K +$383K +21,800 New
SMH
50
Sanders Morris Harris
Texas
$388K – – –
1
2
3 4

CRNX Hedge Fund Activity: Q2 2021 in Review

83 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2021, worth a combined $661M — up 42% from $465M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new CRNX positions and 9 closed out — a net gain of 3 holders — while 47 added to existing stakes and 13 trimmed.

The largest buyer was Driehaus Capital Management, adding an estimated $12.4M. The largest seller was Versant Venture Management, cutting an estimated $21.3M.

  • 83 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2021, up from 80 in Q1 2021.
  • Funds reported $661M of Crinetics Pharmaceuticals stock for Q2 2021, up 42% quarter-over-quarter.
  • 12 funds opened new Crinetics Pharmaceuticals positions in Q2 2021 and 9 closed out, a net change of +3 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q2 2021 was Driehaus Capital Management, an estimated $12.4M added.
  • The largest Crinetics Pharmaceuticals seller in Q2 2021 was Versant Venture Management, an estimated $21.3M sold.

Based on aggregated 13F filings for Q2 2021.